Literature DB >> 30283890

Flare-Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [18F]-NaF PET/CT Study and a Systematic Review.

E Marelise W Eekhoff1, J Coen Netelenbos1, Pim de Graaf2, Max Hoebink1, Nathalie Bravenboer3, Dimitra Micha3, Gerard Pals3, Teun J de Vries4, Adriaan A Lammertsma2, Pieter Ghm Raijmakers2, Robert Jj van Es5.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder leading to progressive heterotopic ossifications (HO) of muscles, tendons, and ligaments, which can be induced by trauma or by surgery. Despite strong medical advice to the contrary, an FOP patient insisted on surgery to alleviate her complete trismus, which caused an unbearable impact on her quality of life (QOL). The entire trismus history of this FOP patient is presented. [18F]-NaF position emission tomography/computed tomography (PET/CT) scans were introduced as an imaging method for heterotopic bone formation activity. To place our findings into context, a systematic review on jaw surgery in FOP was performed. After falling down the stairs, a 9-year-old patient developed mobility impairment of her left-sided jaw. During the following 13 years bone scintigraphy showed persistent activity of the disease leading to progressive left-sided zygomatico-mandibular fusion by HO, resulting in complete trismus. Within 1 month after HO removal on the left side and a matching right coronoidectomy, [18F]-NaF PET/CT demonstrated a substantial flare-up activity followed by new HO in both masseter and temporalis muscles. Despite recurrent HO and trismus her QOL increased due to a stable increased interincisal opening of 5.5 mm. Although systematic review reveals a 100% risk of HO recurrence after jaw surgery, information on improved QOL is scarce. In conclusion, surgery in FOP may be beneficial for QOL despite new HO formation. Assessment of disease activity using [18F]-NaF PET/CT is possible before HO is evident on CT and may serve as a new and quantitative marker of the disease.
© 2017 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.

Entities:  

Keywords:  FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FLARE‐UP; FOP; HETEROTOPIC OSSIFICATION; HO; MAXILLOFACIAL SURGERY; SYSTEMATIC REVIEW; TRISMUS; [18F]‐NAF PET/CT

Year:  2017        PMID: 30283890      PMCID: PMC6124206          DOI: 10.1002/jbm4.10008

Source DB:  PubMed          Journal:  JBMR Plus        ISSN: 2473-4039


Introduction

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder causing progressive heterotopic ossification (HO) of muscles, tendons, and ligaments.1, 2 The activating R206H mutation of the bone morphogenetic protein (BMP) type 1 receptor ACVR1 accounts for most of the classical FOP cases.3, 4 From early childhood onward, the disease becomes gradually worse owing to active periods (flare‐ups), which may be spontaneous or induced by trauma or surgery.5 The underlying mechanism of flare‐ups is complex and not well understood, no validated biomarkers of flare‐ups exist. One early complication of HO is represented by trismus, or restricted jaw opening, which occurs in 70% of patients at a mean age of 19 years and restricts quality of life (QOL) by interfering with essential functions such as eating, vomiting, and oral hygiene.6, 7 There is no proven treatment for FOP and surgery is contraindicated.8 This work presents the medical history and QOL of an FOP patient, who developed a complete trismus and insisted on maxillofacial surgery to augment her interincisal distance (ID) while accepting the risks of recurrent HO. For the first time 18F‐sodiumfluoride position emission tomography/computed tomography ([18F]‐NaF PET/CT) scans were performed as a potential marker of flare‐ups.9 Results are placed into context by relating them to the outcome of a systematic review on the impact of maxillofacial surgery in FOP.

Methods

[18F]‐NaF PET/CT

[18F]‐NaF PET/CT scans were performed at 1, 6, and 12 months after surgery. Sixty minutes after injection of 1.2 MBq · kg−1 [18F]‐NaF, whole‐body PET images were acquired using a Gemini TF‐64 PET/CT scanner (Philips Medical Systems, Best, The Netherlands). Low‐dose CT images (30 mAs) were used for attenuation correction. 18F activity in regions of interest (ROIs) was expressed as standardized uptake value (SUV)10 reflecting early mineralization. HO was expressed in Hounsfield units (HU) derived from the CT images. SUV and HU values from ROIs were compared with reference areas of normal gluteus muscle and of the mandibular symphyseal bone.

Systematic review

A literature search on maxillofacial surgery in FOP was performed in Medline, EMBASE, and Cochrane Library databases from inception until the middle of September 2016. The (MESH) terms and strategy used are summarized in Supporting Table  1. Nine studies on 10 case histories were included. Supporting Fig.  1 shows the inclusion process based on the Preferred Reporting Items for Systematic Reviews.

Results

A 9‐year‐old girl developed a progressive trismus after falling down the stairs onto her face. Six and one‐half weeks later a CT scan demonstrated HO between the left mandibular coronoid process and zygomatic bone. Because of malformations of the big toes and other areas of HO, the diagnosis of classical FOP was made, which was later genetically confirmed. Repeated bone scintigraphy showed increased activity in the left inner parazygomatic region, extending to the left inner paramaxillary region, with slow increase of local HO without signs of clinical flare‐up during the following 13 years. Six years after the fall the patient was completely unable to open her jaw, which seriously compromised her social and essential functions. She urgently requested for surgery, which was initially declined in line with the international expert advice. After 13.9 years she developed a chronic pericoronitis of her lower wisdom teeth, which required their removal. At this point she had a debilitating fear of nausea and choking resulting in frequent visits to the emergency department. After careful considerations, her request for surgery was accepted by a maxillofacial surgeon (RvE) experienced in treatment of craniofacial malformations. Under general anesthesia using fiber‐optic nasoendotracheal intubation, ostectomy of the left‐sided zygomatico‐mandibular bony fusion was executed and the buccal fat pad was interposed. Because ID only increased to 24 mm, right coronoidectomy was performed, leading to an ID of 35 mm immediately after surgery. Also her four wisdom teeth were removed. Preoperatively, the patient received 100 mg prednisolone intravenously, which was continued orally with a dose of 100 mg per day for 1 week in combination with a nonsteroidal anti‐inflammatory drug and prophylactic antibiotic therapy. One week postoperatively the ID already had decreased to 21 mm. Two weeks after the operation, she started frequent exercises with a Therabite (Atos Medical Inc., West Allis, WI, USA), a hand‐operated device that aims to restore jaw mobility. Prednisolone treatment was slowly tapered off, but was repeated three times during the following 4.3 months as a consequence of clinical flare‐ups and related imaging results. Subsequent [18F]‐NaF PET/CT scans 1, 6, and 12 months after surgery, showed local increased muscle 18F uptake on both sides of the masseter and the temporalis muscle regions. After 1 year only new HO had been formed at these locations, resulting in a bony fusion of the mandibular ramus with the zygomatic bone as depicted in Figs. 1 A–C and 2 A–C. Table 1 summarizes the main imaging results at follow‐up.
Figure 1

Axial [18F]‐NaF PET/CT images of the skull at (A) 1 month, (B) 6 months, and (C) 12 months PO. Upper panels show increased uptake of [18F]‐NaF as indicated by means of SUV. Lower panels show possibly HO after 1 month, increasing HO at 6 and 12 months as indicated by means in HU. PO = postoperatively; SUV = standardized uptake value; HO = heterotopic ossification; HU = Hounsfield units.

Figure 2

3D‐CT scan reconstruction of the skull in left (upper panel) and right (lower panel) lateral view before bilateral coronoidectomy (A), 20 days (B), and 12 months (C) PO. Heterotopic lesions are marked by red circles. PO = postoperatively.

Table 1

Results of [18F]‐NaF PET/CT After Maxillofacial Surgery

Indices postsurgeryLeft masseter muscle regionRight masseter muscle region
Mean SUV
Ref.: SUV gluteus muscle0.70.7
After 1 month12.419.0
After 6 months23.316.2
After 12 months10.69.6
AUC 1 year190.95165.67
Mean HU
Ref.: HU over mandibular bone14501450
After 1 month5349
After 6 months381643
After 12 months739892

SUV = standardized uptake value of 18F of 18F‐NaF PET/scan; Ref. = reference value not affected area; AUC = area under the curve; HU = Hounsfield unit of measured CT area of 18F‐NaF PET/scan.

Axial [18F]‐NaF PET/CT images of the skull at (A) 1 month, (B) 6 months, and (C) 12 months PO. Upper panels show increased uptake of [18F]‐NaF as indicated by means of SUV. Lower panels show possibly HO after 1 month, increasing HO at 6 and 12 months as indicated by means in HU. PO = postoperatively; SUV = standardized uptake value; HO = heterotopic ossification; HU = Hounsfield units. 3D‐CT scan reconstruction of the skull in left (upper panel) and right (lower panel) lateral view before bilateral coronoidectomy (A), 20 days (B), and 12 months (C) PO. Heterotopic lesions are marked by red circles. PO = postoperatively. Results of [18F]‐NaF PET/CT After Maxillofacial Surgery SUV = standardized uptake value of 18F of 18F‐NaF PET/scan; Ref. = reference value not affected area; AUC = area under the curve; HU = Hounsfield unit of measured CT area of 18F‐NaF PET/scan. Despite renewed trismus there was stable increased ID, of +5.5 mm 2 years after surgery. One year after surgery the patient felt no fear for vomiting and was no longer depressed. She had improved oral hygiene and regained an emotionally stable and socially active life. A slight anterior open bite was cosmetically acceptable. The patient rated her overall well‐being improved with an increase of six points on a well‐being visual analogue scale of 0 to 10. Notably, no changes in inflammatory or bone‐related parameters were noticed in the laboratory analyses during the flare‐up as summarized in Supporting Table  2. The systematic review revealed a recurrent HO with trismus after maxillofacial surgery in all 10 published case reports. No therapy or surgical procedure could prevent this (Supporting Table  3). Mean surgical follow‐up was 2.2 years (range, 0.8 to 14 years). Postoperatively the ID decreased in all but one patient.

Discussion

This study confirms that maxillofacial surgery and removal of HO in a patient with FOP results in a flare‐up, leading to recurrent and new HO in the region, where surgery was performed. However, despite renewed trismus, the QOL of this patient improved remarkably due to the net increased ID. A systematic review of the literature supports the findings in this case and suggests a 100% risk of recurrent HO after maxillofacial surgery with or without further intervention. Only one case report addressed the improvement in well‐being and reported a similar reduction of trismus.11 Following removal of HO from other sites of the body a recurrence rate of HO of 70% to 90% has been reported.7, 11 Early detection of the postoperative flare‐up was possible using [18F]‐NaF PET/CT. Previously, 99mTechnetium bone scintigraphy has been used in FOP for only diagnostic purposes.8 [18F]‐NaF PET/CT has the advantage that it combines the high sensitivity of PET with precise CT localization. In [18F]‐NaF PET/CT, the exchange of the 18F ions with hydroxyl groups in the hydroxyapatite crystal of bone [Ca10(PO4)6OH2] during the process of mineralization reflects osteoblast activity, which allows for quantification of bone formation in vivo.10, 12 This technique has been validated in studies showing a correlation between 18F uptake and bone histomorphometric findings.12, 13 [18F]‐NaF PET/CT shows increased physiological bone formation within 2 weeks after allograft replacement in healthy persons.9 In the present case markedly increased fluoride uptake in muscles was shown already at the first [18F]‐NaF PET/CT scan 1 month after surgery. New HO only developed within muscle regions where increased 18F activity was seen, predicting the location of HO formation at an early stage. To the best of our knowledge this is the first time FOP disease activity was demonstrated during a defined flare‐up. With the aid of this new diagnostic tool, the pathophysiology of mysterious flare‐ups in FOP may become better understood. In conclusion, maxillofacial surgery in FOP can be beneficial for the patient despite exacerbation of the disease, but should remain a management choice of last resort. [18F]‐NaF PET/CT is a promising technique to characterize and quantify flare‐ups in FOP, and therefore could become a new tool in proof‐of‐concept trials to evaluate novel drugs designed to prevent HO.

Disclosures

All authors state that they have no conflicts of interest. Supporting Data S1. Click here for additional data file.
  13 in total

1.  Assessment of porcine bone metabolism by dynamic.

Authors:  M Piert; T T Zittel; G A Becker; M Jahn; A Stahlschmidt; G Maier; H J Machulla; R Bares
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

2.  Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva.

Authors:  Nathalie Bravenboer; Dimitra Micha; James T Triffit; Alex N Bullock; Roberto Ravazollo; Renata Bocciardi; Maja di Rocco; J Coen Netelenbos; Peter Ten Dijke; Gonzalo Sánchez-Duffhues; Fred S Kaplan; Eileen M Shore; Robert J Pignolo; Petra Seemann; Francesc Ventura; Genevieve Beaujat; Elizabeth M W Eekhoff; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2015-01-21       Impact factor: 4.246

3.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

4.  Quantification of 18F-Fluoride Kinetics: Evaluation of Simplified Methods.

Authors:  Pieter Raijmakers; Olivier P P Temmerman; Carrol P Saridin; Ide C Heyligers; Alfred G Becking; Arthur van Lingen; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2014-05-27       Impact factor: 10.057

Review 5.  Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

6.  Fibrodysplasia ossificans progressiva. A survey of forty-two cases.

Authors:  J G Rogers; W B Geho
Journal:  J Bone Joint Surg Am       Date:  1979-09       Impact factor: 5.284

7.  Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients.

Authors:  J M Connor; D A Evans
Journal:  J Bone Joint Surg Br       Date:  1982

8.  Bone metabolism after total hip revision surgery with impacted grafting: evaluation using H2 15O and [18F]fluoride PET; a pilot study.

Authors:  Olivier P P Temmerman; Pieter G H M Raijmakers; Ide C Heyligers; Emile F I Comans; Mark Lubberink; Gerrit J J Teule; Adriaan A Lammertsma
Journal:  Mol Imaging Biol       Date:  2008-06-10       Impact factor: 3.488

9.  The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.

Authors:  Robert J Pignolo; Christopher Bedford-Gay; Moira Liljesthröm; Blythe P Durbin-Johnson; Eileen M Shore; David M Rocke; Frederick S Kaplan
Journal:  J Bone Miner Res       Date:  2015-11-14       Impact factor: 6.741

10.  (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.

Authors:  J C Regelink; P G Raijmakers; N Bravenboer; R Milek; N J Hoetjes; A M de Kreuk; M van Duin; M J Wondergem; P Lips; P Sonneveld; J M Zijlstra; S Zweegman
Journal:  EJNMMI Res       Date:  2016-05-31       Impact factor: 3.138

View more
  13 in total

Review 1.  Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.

Authors:  Kelly L Wentworth; Umesh Masharani; Edward C Hsiao
Journal:  Br J Clin Pharmacol       Date:  2019-01-06       Impact factor: 4.335

Review 2.  Do Interactions of Vitamin D3 and BMP Signaling Hold Implications in the Pathogenesis of Fibrodysplasia Ossificans Progressiva?

Authors:  Jessica L Pierce; Daniel S Perrien
Journal:  Curr Osteoporos Rep       Date:  2021-04-14       Impact factor: 5.163

Review 3.  Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors:  Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal:  Neurosci Biobehav Rev       Date:  2021-02-10       Impact factor: 9.052

4.  Longitudinal Evaluation of Pain, Flare-Up, and Emotional Health in Fibrodysplasia Ossificans Progressiva: Analyses of the International FOP Registry.

Authors:  Ke Peng; Kin Cheung; Arielle Lee; Christine Sieberg; David Borsook; Jaymin Upadhyay
Journal:  JBMR Plus       Date:  2019-03-01

5.  Tailored Teaching for Specialized (Para-)medical Students - Experience From Incorporating a Relevant Genetic Disease Throughout a Course of Molecular Cell Biology.

Authors:  Ton Schoenmaker; Dongmei Deng; Teun J de Vries
Journal:  Front Public Health       Date:  2020-07-09

6.  Diagnostic Value of Magnetic Resonance Imaging in Fibrodysplasia Ossificans Progressiva.

Authors:  Esmée Botman; Bernd P Teunissen; Pieter Raijmakers; Pim de Graaf; Maqsood Yaqub; Sanne Treurniet; Ton Schoenmaker; Nathalie Bravenboer; Dimitra Micha; Gerard Pals; Arend Bökenkamp; J Coen Netelenbos; Adriaan A Lammertsma; Elisabeth Mw Eekhoff
Journal:  JBMR Plus       Date:  2020-04-28

7.  Collaboration Around Rare Bone Diseases Leads to the Unique Organizational Incentive of the Amsterdam Bone Center.

Authors:  Elisabeth M W Eekhoff; Dimitra Micha; Tymour Forouzanfar; Teun J de Vries; J Coen Netelenbos; Jenneke Klein-Nulend; Jack J W A van Loon; Wouter D Lubbers; Lothar Schwarte; Patrick Schober; Pieter G H M Raijmakers; Bernd P Teunissen; Pim de Graaf; Adriaan A Lammertsma; Maqsood M Yaqub; Esmée Botman; Sanne Treurniet; Bernard J Smilde; Arend Bökenkamp; Anco Boonstra; Otto Kamp; Jakko A Nieuwenhuijzen; Marieke C Visser; Hans J C Baayen; Max Dahele; Guus A M Eeckhout; Thadé P M Goderie; Cas Smits; Marjolijn Gilijamse; K Hakki Karagozoglu; Paul van de Valk; Chris Dickhoff; Annette C Moll; Frank F D Verbraak; Katie K R Curro-Tafili; Ebba A E Ghyczy; Thomas Rustemeyer; Peeroz Saeed; Alessandra Maugeri; Gerard Pals; Angela Ridwan-Pramana; Esther Pekel; Ton Schoenmaker; Willem Lems; Henri A H Winters; Matthijs Botman; Georgios F Giannakópoulos; Peter Koolwijk; Jeroen J W M Janssen; Peter Kloen; Nathalie Bravenboer; Jan Maerten Smit; Marco N Helder
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-11       Impact factor: 5.555

Review 8.  Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP).

Authors:  Edward C Hsiao; Maja Di Rocco; Amanda Cali; Michael Zasloff; Mona Al Mukaddam; Robert J Pignolo; Zvi Grunwald; Coen Netelenbos; Richard Keen; Genevieve Baujat; Matthew A Brown; Tae-Joon Cho; Carmen De Cunto; Patricia Delai; Nobuhiko Haga; Rolf Morhart; Christiaan Scott; Keqin Zhang; Robert J Diecidue; Clive S Friedman; Fredrick S Kaplan; Elisabeth M W Eekhoff
Journal:  Br J Clin Pharmacol       Date:  2018-11-06       Impact factor: 4.335

9.  Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.

Authors:  Sukhmani Singh; Joseph Kidane; Kelly L Wentworth; Daria Motamedi; Saam Morshed; Andrew E Schober; Edward C Hsiao
Journal:  BMC Musculoskelet Disord       Date:  2020-04-03       Impact factor: 2.362

10.  Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature.

Authors:  Esmée Botman; Jan Coen Netelenbos; Thomas Rustemeyer; Linda J Schoonmade; Jakko A Nieuwenhuijzen; Bernd P Teunissen; Marieke Visser; Pieter Raijmakers; Adriaan A Lammertsma; Max Dahele; Marelise Eekhoff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-12       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.